Hepatic Steatosis Diagnosis and Management

Definition and Prevalence

Metabolic dysfunction-associated steatotic liver disease (MASLD) has a prevalence of 20-30% in the general population, increasing to 70% in obesity and 90% in diabetes, according to the American College of Radiology 1

Ultrasound is commonly used as first-line investigation, showing increased liver echogenicity compared to renal cortex, with a sensitivity of 84.8% and specificity of 93.6% for moderate to severe hepatic fat deposition, as recommended by the American College of Radiology 1
Grading of steatosis by ultrasound includes mild, moderate, and severe, with the American College of Radiology recommending the use of the hepatorenal index for more objective evaluation 1

Simple hepatic steatosis may remain benign without cellular insult in 70-75% of MASLD cases, while steatohepatitis occurs in 25-30% of cases, featuring hepatocyte injury and inflammation, according to the American College of Radiology 1 and Diabetologia 5
Progressive inflammation can lead to fibrosis, cirrhosis, and hepatocellular carcinoma, with the AST:ALT ratio helping to differentiate causes, as reported by the American College of Radiology 1 and Diabetologia 5

Increased liver echogenicity should prompt evaluation for fatty liver disease, especially in patients with risk factors, with initial evaluation including liver biochemistries and exclusion of other liver diseases, as recommended by the American College of Radiology 1 and Praxis Medical Insights 4
Management focuses on lifestyle modifications, optimal management of comorbidities, and consideration of incretin-based therapies for type 2 diabetes or obesity, according to Diabetologia 6 and 7
Bariatric surgery is an option for those with obesity, as reported by Diabetologia 6 and 7